Tech Company Financing Transactions
Tisento Therapeutics Funding Round
On 8/1/2023, Tisento Therapeutics landed $81 million in Series A financing from Cyclerion Therapeutics, private investors and Invus.
Transaction Overview
Company Name
Announced On
8/1/2023
Transaction Type
Venture Equity
Amount
$81,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for the development of the Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat in MELAS and other genetic mitochondrial diseases, as well as the advancement of additional assets for serious diseases with unmet need.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA Undisclosed
USA
Cambridge, MA Undisclosed
USA
Phone
Undisclosed
Email Address
Overview
Developer of medicine intended to treat diseases with significant unmet medical needs. The company's product help to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Hecht
Chief Operating Officer
G. Todd Milne
Browse more venture capital transactions:
Prev: 8/1/2023: ConfiAbogado venture capital transaction
Next: 8/1/2023: Konscious Foods venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs